Anulex Technologies has received US Food and Drug Administration (FDA) approval for its fiXate Tissue Band, designed to secure spinal cord stimulation lead anchors to the fascia or interspinous / supraspinous ligament in patients with chronic, intractable pain of the trunk or limbs.

The fiXate Tissue Band provides consistent anchor securement through a delivery system that facilitates efficient fixation to the surrounding tissue.

Anulex executive chairman Jeff Peters said that, with the clearance of the fiXate Tissue Band, Anulex continues to demonstrate its commitment to developing novel and clinically relevant solutions for soft tissue fixation and repair.